The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.
 
Mark Stares
No Relationships to Disclose
 
Samra Turajlic
No Relationships to Disclose
 
Andrew J.S. Furness
No Relationships to Disclose
 
Kroopa Joshi
No Relationships to Disclose
 
David Nicol
No Relationships to Disclose
 
Martin Eric Gore
No Relationships to Disclose
 
Lisa M. Pickering
Honoraria - GlaxoSmithKline; Pfizer
Consulting or Advisory Role - Astellas Pharma; Janssen; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
 
Nicos Fotiadis
No Relationships to Disclose
 
Steve Hazell
No Relationships to Disclose
 
Aspasia Soultati
No Relationships to Disclose
 
Andrew Rowan
No Relationships to Disclose
 
Karen O'Meara
No Relationships to Disclose
 
Karl Peggs
Consulting or Advisory Role - Autolus; Basilea; Chimerix; Clinigen Group; Merck; Takeda
Speakers' Bureau - Merck; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Cell Medica; Merck; Takeda
 
Charles Swanton
Stock and Other Ownership Interests - Apogen Biotechnologies; Epic Sciences
Honoraria - Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Ono Pharmaceutical; Roche; SERVIER
Research Funding - Boehringer Ingelheim
 
Sergio Quezada
No Relationships to Disclose
 
James M. G. Larkin
Research Funding - Novartis (Inst); Pfizer (Inst)